Cargando…

Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches

Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer. However, advanced tumors develop resistance to endocrine therapy, rendering it ineffective as the disease progresses. There are several molecular mechanisms of primary and secondary endocrine resistance. Resis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raheem, Farah, Karikalan, Suganya Arunachalam, Batalini, Felipe, El Masry, Aya, Mina, Lida
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671474/ https://www.ncbi.nlm.nih.gov/pubmed/38003387 http://dx.doi.org/10.3390/ijms242216198

Ejemplares similares

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

Immune checkpoint inhibitor myocarditis with complete heart block: a case series
por: O'shea, M, et al.
Publicado: (2023)

Complete heart block is a significant predictor of mortality in immune checkpoint inhibitor myocarditis
por: O’Shea, Michael P., et al.
Publicado: (2023)

ERS Presidential Summit: redesigning the future of patient care
por: Gaga, Mina
Publicado: (2019)

The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches
por: Jefferi, Nur Erysha Sabrina, et al.
Publicado: (2023)

Intracardiac Thrombus in Coronavirus Disease-2019
por: Karikalan, Suganya, et al.
Publicado: (2022)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

A Rare Case of Anomalous Origin of Left Anterior Descending Artery From Right Coronary Ostium
por: Karikalan, Suganya, et al.
Publicado: (2021)

Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer
por: Lainé, Muriel, et al.
Publicado: (2021)

New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future
por: Cidon, Esther Una
Publicado: (2017)

Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer
por: Finnegan, Ryan M., et al.
Publicado: (2022)

Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches
por: Geurts, Veerle, et al.
Publicado: (2023)

Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
por: Schick, Jason, et al.
Publicado: (2021)

A CREB3-regulated ER-Golgi trafficking signature promotes metastatic progression in breast cancer
por: Howley, Breege V, et al.
Publicado: (2017)

BP1 Homeoprotein Enhances Metastatic Potential in ER-negative Breast Cancer
por: Fu, Yebo, et al.
Publicado: (2010)

ODP647 Nuclear ERα and NAMPT Crosstalk in Metastatic Breast Tumors
por: Mogol, Ayca, et al.
Publicado: (2022)

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

PIWI-like protein, HIWI2 is aberrantly expressed in retinoblastoma cells and affects cell-cycle potentially through OTX2
por: Sivagurunathan, Suganya, et al.
Publicado: (2017)

Secondary hemophagocytic lymphohistiocytosis in the setting of metastatic renal cell carcinoma: a case report
por: El-Masry, Monica, et al.
Publicado: (2017)

Endogenous and Therapeutic Estrogens: Maestro Conductors of the Microenvironment of ER+ Breast Cancers
por: Schuler, Linda A., et al.
Publicado: (2021)

Isolation and Characterization of a Metastatic Hybrid Cell Line Generated by ER Negative and ER Positive Breast Cancer Cells in Mouse Bone Marrow
por: Mukhopadhyay, Keya De, et al.
Publicado: (2011)

FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype
por: Levine, Kevin M., et al.
Publicado: (2019)

Challenges in Predicting Future Costs for Metastatic Breast Cancer
por: Dinan, Michaela A, et al.
Publicado: (2021)

The Present and Future of Clinical Management in Metastatic Breast Cancer
por: Lin, Pauline H., et al.
Publicado: (2022)

Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023)

Decoding the Therapeutic Implications of the ERα Stability and Subcellular Distribution in Breast Cancer
por: Tecalco-Cruz, Angeles C., et al.
Publicado: (2022)

A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109
por: Mina, Lida A., et al.
Publicado: (2013)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
por: Kaminska, Kamila, et al.
Publicado: (2021)

Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
por: Van Baelen, Karen, et al.
Publicado: (2023)

Ouabain and Digoxin Activate the Proteasome and the Degradation of the ERα in Cells Modeling Primary and Metastatic Breast Cancer
por: Busonero, Claudia, et al.
Publicado: (2020)

Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
por: Paoletti, Costanza, et al.
Publicado: (2021)

Age-associated microenvironmental changes highlight the role of PDGF-C in ER(+) breast cancer metastatic relapse
por: Turrell, Frances K., et al.
Publicado: (2023)

Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach for Staphylococcus aureus In Vivo Infection
por: Alshawwa, Samar Zuhair, et al.
Publicado: (2023)

ASSESSMENT OF THE POSTERIOR APPROACH FOR SURGICAL TREATMENT OF SPINAL METASTATIC BREAST CANCER
por: Pontes, Mariana Demétrio de Sousa, et al.
Publicado: (2020)

The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER(+) breast cancer with mitotic aberrations
por: Soria-Bretones, Isabel, et al.
Publicado: (2022)

Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer
por: Rahem, Sarra M., et al.
Publicado: (2020)

The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches
por: Ades, Felipe, et al.
Publicado: (2017)

ER-α36: a novel biomarker and potential therapeutic target in breast cancer
por: Su, Xingyun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_r87qkdt85rne7ngfjfpavaa327